Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Kura Oncology, Inc.

NASDAQ: KURA · Life Sciences · 3 alerts · CIK 1422143

Share price
$7.09Close, Nov 16
Market cap
$651M
Shares outstanding
91.88MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kura Oncology, Inc. filings on SEC EDGAR ↗

7:46 PM ET Form 4
Insider Buying

Kura Oncology President and CEO Troy Edward Wilson Buys $1.5M of Stock

Troy Edward Wilson, President and CEO, bought 200,000 shares of Kura Oncology, Inc. at $7.42 to $7.63 a share (average $7.52) in 2 transactions, worth $1.5M in total between Nov 13, 2026 and Nov 16, 2026. Shares held after the trade: 635,456 (+18.9%).

Value
$1.5M
Shares
200,000
Average price
$7.52
Role
President and CEO
Holding change
+18.9%
Trade date
Nov 13, 2026 to Nov 16, 2026
4:11 PM ET 10-Q
Financial Results

Kura Oncology Q3 2026 Results: Net Loss of $70.2M, Loss Narrows

Kura Oncology reported total revenue of $22.8 million for Q3 2026, driven by the introduction of $13.9 million in product revenue. Despite this, the company recorded a net loss of $70.2 million for the quarter and $211.9 million for the first nine months of 2026, with total stockholders' equity declining significantly to $18.0 million from $174.1 million at year-end 2025.

Key figure
Net loss $70.2M
4:06 PM ET 8-K
Financial Results

Kura Oncology Financial Results

Kura Oncology reported Q3 2026 financial results, highlighted by $13.9 million in net product revenue for KOMZIFTI, representing 53% sequential growth. The company reached FDA alignment on a registrational study design for darlifarnib in salivary gland cancer and secured a strategic financing agreement with Oberland Capital for up to $300 million.

Term
Q3 2026

“KOMZIFTI delivered strong commercial performance this quarter, with 53% sequential revenue growth, a 30% increase in new patients starts, and continued majority share of new patient starts. We believe these results demonstrate the growing commercial potential of KOMZIFTI and provide a strong foundation as we advance ziftomenib into the substantially larger frontline AML opportunity.”

Troy Wilson, Ph.D., J.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.